Last update: July 14, 2015

Carteolol Ophtalmic Use

Very Low Risk for breastfeeding


Safe. Compatible.
Minimal risk for breastfeeding and infant.

At date of last update were not found published data on its excretion into breast milk.

Because of a small dose and low absorption to the plasma in a majority of ophthalmic preparations that are topically used, a significant excretion into the milk is unlikely, thus it is considered of very low risk while breastfeeding in this cases. It would be advisable to press on the lacrimal area or tightly close the eyes for a couple of minutes (nasolacrimal occlusion) to minimize the systemic absorption.

The risk can be further minimized by the use of beta-blocking agents with a higher protein-binding capacity.

Alternatives

We do not have alternatives for Carteolol Ophtalmic Use since it is relatively safe.

Suggestions made at e-lactancia are done by APILAM´s pediatricians and pharmacists, and are based on updated scientific publications.
It is not intended to replace the relationship you have with your doctor but to compound it.

Jose Maria Paricio, Founder & President of APILAM/e-Lactancia

Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.

Thank you for helping to protect and promote breastfeeding.

José María Paricio, founder of e-lactancia.
DONATE NOW

Other names

Carteolol Ophtalmic Use is also known as


Group

Carteolol Ophtalmic Use belongs to this group or family:

Tradenames

Main tradenames from several countries containing Carteolol Ophtalmic Use in its composition:

Pharmacokinetics

Variable Value Unit
Oral Bioavail. 80 %
Molecular weight 329 daltons
Protein Binding 25 %
VD 2,5 - 7 l/Kg
Tmax 2 hours
T1/2 6 - 8 hours

References

  1. Tamargo Menéndez J, Delpón Mosquera E. Farmacología de los bloqueantes de los receptores β-adrenérgicos. Curso βeta 2011 de Actualización en Betabloqueantes. 2011 Full text (in our servers)
  2. Carteolol. Ficha técnica. 2009 Full text (in our servers)
  3. Renard P, Kovalski JL, Cochereau I, Jaulerry S, Williamson W, Elena PP, Lablache Combier M, Allaire C, Siou-Mermet R. Comparison of carteolol plasmatic levels after repeated instillations of long-acting and regular formulations of carteolol 2% in glaucoma patients. Graefes Arch Clin Exp Ophthalmol. 2005 Abstract
  4. Riant P, Urien S, Albengres E, Duche JC, Tillement JP. High plasma protein binding as a parameter in the selection of betablockers for lactating women. Biochem Pharmacol. 1986 Abstract
  5. Ishizaki T, Ohnishi A, Sasaki T, Kushida K, Horai Y, Chiba K, Suganuma T. Pharmacokinetics and absolute bioavailability of carteolol, a new beta-adrenergic receptor blocking agent. Eur J Clin Pharmacol. 1983 Abstract

Total visits

1,523

Help us improve this entry

How to cite this entry

Do you need more information or did not found what you were looking for?

   Write to us at elactancia.org@gmail.com

e-lactancia is a resource recommended by Academy of Breastfeeding Medicine - 2006 from United States of America

Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM